Final analysis of phase I study of ceritinib in pediatric patients with malignancies harboring activated anaplastic lymphoma kinase (ALK).

被引：1
|
作者：
Schulte, Johannes H.
Moreno, Lucas
Ziegler, David Simon
Marshall, Lynley V.
Zwaan, C. Michel
Irwin, Meredith
Casanova, Michela
Sabado, Constantino
Wulff, Beate
Stegert, Mario
Wang, Luojun
Hurtado, Felipe K.
Branle, Fabrice
Fischer, Matthias
Geoerger, Birgit
机构：
[1] Charite Berlin Campus Virchow Klinikum, Berlin, Germany
[2] Hosp Univ Nino Jesus, Madrid, Spain
[3] Sydney Childrens Hosp, Kids Canc Ctr, Randwick, NSW, Australia
[4] Royal Marsden Hosp, London, England
[5] Inst Canc Res, London, England
[6] Sophia Childrens Univ Hosp, Erasmus MC, Rotterdam, Netherlands
[7] Princess Maxima Ctr Pediat Oncol Utrecht, Rotterdam, Netherlands
[8] Hosp Sick Children, Toronto, ON, Canada
[9] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[10] Hosp Valle De Hebron, Barcelona, Spain
[11] Univ Childrens Hosp III Essen, Essen, Germany
[12] Novartis Pharma AG, Basel, Switzerland
[13] Novartis Pharmaceut, E Hanover, NJ USA
[14] Novartis Inst Biomed Res, Oncol Clin Pharmacol, E Hanover, NJ USA
[15] Novartis Pharmaceut AG, Basel, Switzerland
[16] Univ Childrens Hosp Cologne, Cologne, Germany
[17] Univ Paris Saclay, Gustave Roussy Canc Ctr, Villejuif, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10505
引用
收藏
页数：2
相关论文
共 50 条
  • [21] CLINICOPATHOLOGIC CHARACTERISTICS OF 12 CHINESE NON-SMALL CELL LUNG CANCER PATIENTS HARBORING ANAPLASTIC LYMPHOMA KINASE (ALK) GENE REARRANGEMENTS
    Ye, M.
    Hu, J.
    Zhang, X.
    Hong, Q.
    Li, C.
    Zhang, J.
    Jiang, J.
    Bai, C.
    RESPIROLOGY, 2011, 16 : 177 - 177
  • [22] Ceritinib plus nivolumab (NIVO) in patients (pts) with anaplastic lymphoma kinase positive (ALK plus ) advanced non-small cell lung cancer (NSCLC).
    Felip, Enriqueta
    De Braud, Filippo G.
    Maur, Michela
    Loong, Herbert H. F.
    Shaw, Alice Tsang
    Vansteenkiste, Johan F.
    John, Tom
    Liu, Geoffrey
    Lolkema, Martijn P.
    Scott, Jeffrey W.
    Yu, Richard
    Selvaggi, Giovanni
    Mishra, Kaushal
    Lau, Yi-Yang Yvonne
    Tan, Daniel Shao-Weng
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [23] Final results from a phase I trial of ixabepilone in patients with advanced malignancies and lymphoma.
    Aghajanian, C.
    O'Connor, O.
    Cohen, M.
    Peck, R.
    Burris, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 88S - 88S
  • [24] Phase I/II trial of X-396, a novel anaplastic lymphoma kinase (ALK) inhibitor, in patients with ALK plus non-small cell lung cancer (NSCLC)
    Reckamp, Karen L.
    Infante, Jeffrey R.
    Blumenschein, George R.
    Wakelee, Heather
    Carter, Corey A.
    Gockerman, Jon P.
    Lovly, Christine
    Dukart, Gary
    Harrow, Kimberly
    Liang, Chris
    Gibbons, James J.
    Horn, Leora
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (02) : S36 - S37
  • [25] Phase I/II trial of X-396, a novel anaplastic lymphoma kinase (ALK) inhibitor, in patients with ALK plus non-small cell lung cancer (NSCLC)
    Lovly, Christine M.
    Infante, Jeffrey R.
    Blumenschein, George R.
    Reckamp, Karen
    Wakelee, Heather
    Carter, Corey A.
    VVagar, Saiama N.
    Neal, Joel
    Gockerman, Jon P.
    Dukart, Gary
    Harrow, Kimberly
    Liang, Chris
    Gibbons, James J.
    Horn, Leora
    CANCER RESEARCH, 2016, 76
  • [26] Cost-effectiveness of ceritinib in patients previously treated with crizotinib in anaplastic lymphoma kinase positive (ALK plus ) non-small cell lung cancer in Canada
    Hurry, Manjusha
    Zhou, Zheng-Yi
    Zhang, Jie
    Zhang, Chenxue
    Fan, Liangyi
    Rebeira, Mayvis
    Xie, Jipan
    JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (10) : 936 - 944
  • [27] COST-EFFECTIVENESS ANALYSIS OF CERITINIB IN PATIENTS PREVIOUSLY TREATED WITH CRIZOTINIB AND CHEMOTHERAPY IN ANAPLASTIC LYMPHOMA KINASE POSITIVE (ALK plus ) NON-SMALL CELL LUNG CANCER IN UNITED STATES
    Zhang, Y.
    Shao, Y.
    Shi, L.
    VALUE IN HEALTH, 2020, 23 : S32 - S32
  • [28] COST-EFFECTIVENESS OF CERITINIB IN PREVIOUSLY TREATED PATIENTS WITH CRIZOTINIB IN ANAPLASTIC LYMPHOMA KINASE-POSITIVE (ALK plus ) NON-SMALL CELL LUNG CANCER IN CANADA
    Zhou, Z.
    Hurry, M.
    Zhang, J.
    Fan, L.
    Zhang, C.
    Xie, J.
    VALUE IN HEALTH, 2015, 18 (07) : A462 - A462
  • [29] Phosphoproteomic analysis of anaplastic lymphoma kinase (ALK) downstream signaling pathways identifies signal transducer and activator of transcription 3 as a functional target of activated ALK in neuroblastoma cells
    Sattu, Kamaraj
    Hochgrafe, Falko
    Wu, Jianmin
    Umapathy, Ganesh
    Schonherr, Christina
    Ruuth, Kristina
    Chand, Damini
    Witek, Barbara
    Fuchs, James
    Li, Pui-Kai
    Hugosson, Fredrik
    Daly, Roger J.
    Palmer, Ruth H.
    Hallberg, Bengt
    FEBS JOURNAL, 2013, 280 (21) : 5269 - 5282
  • [30] PHASE 1/2 STUDY OF AP26113 IN PATIENTS (PTS) WITH ADVANCED MALIGNANCIES, INCLUDING ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC): ANALYSIS OF SAFETY AND EFFICACY AT SELECTED PHASE 2 DOSES
    Rosell, R.
    Gettinger, S.
    Bazhenova, L. A.
    Langer, C. J.
    Salgia, R.
    Gold, K.
    Shaw, A. T.
    Dorer, D. J.
    Kerstein, D.
    Camidge, D. R.
    ANNALS OF ONCOLOGY, 2015, 26
12345